GlassScriptPhysician profile
Lindsay Lee
NPI 1538451943
$4,256.08
in general payments reported to CMS, 2019-2025
14 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $205 · 2023: $1,864 · 2024: $1,924 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,770 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,212 · Food and Beverage: $1,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,770.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,212.00 |
| Food and Beverage | $1,069.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,527.20 | 2024 | Xospata |
| Sanofi-Aventis U.S. LLC | $1,169.73 | 2023-2024 | |
| Celgene Corporation | $600.00 | 2023-2024 | Reblozyl |
| Stemline Therapeutics INC. | $187.68 | 2023 | Orserdu |
| Genzyme Corporation | $170.03 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.31 | 2025 | |
| Servier Pharmaceuticals LLC | $133.56 | 2023 | |
| Amgen INC. | $107.63 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.09 | 2022 | |
| Janssen Biotech, INC. | $30.46 | 2025 | Tecvayli |
| Novartis Pharmaceuticals Corporation | $30.08 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.57 | 2025 | Imfinzi |
| Azurity Pharmaceuticals, INC. | $16.64 | 2025 | Vivimusta |
| Merck Sharp & Dohme LLC | $16.10 | 2025 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.